

Applicants: David J. Pinsky, et al.
Serial No.: 10/692,439
Filed: October 22, 2003
Page 2

Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application:

1. (Original) A method for treating an ischemic disorder in a subject which comprises administering to the subject a pharmaceutically acceptable form of a Factor IXa compound in a sufficient amount over a sufficient period of time to inhibit coagulation so as to treat the ischemic disorder in the subject.
2. (Original) A method for treating an ischemic disorder in a subject which comprises administering to the subject a pharmaceutically acceptable form of a Factor IXa compound and a pharmaceutically acceptable form of an indirect or direct fibrinolytic agent, each in a sufficient amount over a sufficient period of time to inhibit coagulation so as to treat the ischemic disorder in the subject.
- 3-20. (Canceled)
21. (Original) A method for identifying a compound that is capable of improving an ischemic disorder in a subject which comprises:
 - a) administering the compound to an animal, which animal is a stroke animal model;
 - b) measuring stroke outcome in the animal; and

- c) comparing the stroke outcome in step (b) with that of the stroke animal model in the absence of the compound so as to identify a compound capable of improving an ischemic disorder in a subject.

22-24. (Canceled)

- 25. (Original) A method for treating a reperfusion injury in a subject which comprises administering to the subject a Factor IXa compound in a sufficient amount over a sufficient period of time to inhibit coagulation so as to treat the reperfusion injury in the subject.

26-28. (Canceled)

- 29. (Original) A method of inhibiting clot formation in a subject which comprises adding to blood an amount of an inactive recombinant mutein in an amount effective to inhibit clot formation in the subject but which does not significantly interfere with hemostasis when the blood is administered to a patient.

30. (Canceled)

- 31. (Original) An assay to monitor the effect of a Factor IXa compound administered to a subject to treat an ischemic disorder in the subject which comprises:

- a) measuring the ischemic disorder in the subject;

Applicants: David J. Pinsky, et al.
Serial No.: 10/692,439
Filed: October 22, 2003
Page 4

- b) administering the Factor IXa compound to the subject and measuring the ischemic disorder and
- c) comparing the measurement of the ischemic disorder in step (b) with that measured in step (a) so as to monitor the effect of the Factor IXa compound.

32. (Canceled)

33. (New) The method of claim 25, wherein the Factor IXa compound comprises recombinant inactivated Factor IXa.

34. (New) The method of claim 33, wherein the Factor IXa compound is a peptide, a peptidomimetic, a nucleic acid, a small molecule, a mutated peptide or nucleic acid, a mutein, an antibody or fragment thereof.

35. (New) The method of claim 33, wherein the Factor IXa compound is a synthetic molecule.